Publications by authors named "Aram Oganesian"

Claim this Profile
U
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs.
Wei Gao, Jiang Liu, Cynthia J Musante, Hao Zhu, Matthew Thompson, Aram Oganesian

Clin Pharmacol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine-cedazuridine in patients with MDS and TP53 mutations.
Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop M Kantarjian, Guillermo Montalban-Bravo, Aram Oganesian

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, Harshad Amin, Amy E DeZern, Aram Oganesian

Br J Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Aram Oganesian

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.
Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet, Aram Oganesian

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Klaus Geissler, Zdenek Koristek, Teresa Bernal Del Castillo, Jan Novák, Gabriela Rodríguez-Macías, Aram Oganesian

Br J Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Aram Oganesian

Lancet Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies.
Vanessa Martins, Lynsey Fazal, Aram Oganesian, Alpesh Shah, Jessie Stow

Xenobiotica· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validated liquid chromatography-tandem mass spectroscopy method for the quantification of tolinapant in human plasma.
Vanessa Martins, Nicola Wilsher, Song Lin, Aram Oganesian

Anal Sci Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Swapna Thota, Aram Oganesian, Mohammad Azab, Elizabeth A Griffiths

Future Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass balance and metabolite profiling of C-guadecitabine in patients with advanced cancer.
Jeroen Roosendaal, Hilde Rosing, Luc Lucas, Abadi Gebretensae, Alwin D R Huitema, Aram Oganesian

Invest New Drugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Guillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, Gail J Roboz, Richard Wells, Aram Oganesian

Blood· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.
Monica M Mita, Patricia M LoRusso, Kyriakos P Papadopoulos, Michael S Gordon, Alain C Mita, Aram Oganesian

Clin Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.
Haley E Ramsey, Aram Oganesian, Agnieszka E Gorska, Londa Fuller, Maria Arrate

Target Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Amit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D Roman, Aram Oganesian

Clin Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
Anna Maria Di Giacomo, Alessia Covre, Francesca Finotello, Dietmar Rieder, Riccardo Danielli, Aram Oganesian

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
Susan Slovin, Syed Hussain, Fred Saad, Jorge Garcia, Joel Picus, Aram Oganesian

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Michael R Savona, Olatoyosi Odenike, Philip C Amrein, David P Steensma, Amy E DeZern, Aram Oganesian

Lancet Haematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.
Jeroen Roosendaal, Kai Wang, Hilde Rosing, Luc Lucas, Abadi Gebretensae, Aram Oganesian

J Chromatogr B Analyt Technol Biomed Life Sci· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2'-deoxycytidine.
Jeroen Roosendaal, Hilde Rosing, Luc Lucas, Aram Oganesian, Jan H M Schellens

J Pharm Biomed Anal· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan.
Valerie Lee, Judy Wang, Marianna Zahurak, Elske Gootjes, Henk M Verheul, Aram Oganesian

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Daniela Matei, Sharad Ghamande, Lynda Roman, Angeles Alvarez Secord, John Nemunaitis, Aram Oganesian

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies.
Cong Xu, Timothy K Goggin, Xiang-Yao Su, Pietro Taverna, Aram Oganesian

CPT Pharmacometrics Syst Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Andrew J Wagner, Mark Agulnik, Michael C Heinrich, Daruka Mahadevan, Richard F Riedel, Aram Oganesian

Eur J Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Jean-Pierre J Issa, Gail Roboz, David Rizzieri, Elias Jabbour, Wendy Stock, Aram Oganesian

Lancet Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis